Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income (loss)	$ 14,384	$ 29,523
Adjustments to reconcile to net cash provided by (used in) operating activities:
Stock-based compensation expense	14,527	11,802
Depreciation and amortization	28,155	25,859
Income taxes	4,814	15,904
Change in fair value of contingent obligations	(1,253)	(10,898)
Write off of debt issuance costs	0	0
Impairment of in-process research and development	0	9,827
Abandonment of long-lived assets	3,749	0
Excess tax benefits from stock-based compensation	(10,825)	(8,002)
Other	2,467	197
Changes in operating assets and liabilities:
Accounts receivable	45,035	1,749
Inventories	(16,183)	(14,396)
Income taxes	(14,662)	(22,707)
Prepaid expenses and other assets	(3,146)	1,010
Accounts payable	(1,305)	1,902
Accrued expenses and other liabilities	(1,699)	(2,060)
Accrued compensation	(152)	(1,688)
Provision for chargebacks	103	(296)
Deferred revenue	(1,348)	3,663
Net cash provided by operating activities	62,661	41,389
Cash flows from investing activities:
Purchases of property, plant and equipment	(56,243)	(33,631)
Acquisition of Cangene Corporation, net of acquired cash	0	0
Net cash used in investing activities	(56,243)	(33,631)
Cash flows from financing activities:
Proceeds from convertible debenture, net of bank fees	0	0
Proceeds from long-term debt obligations	0	2,000
Issuance of common stock upon exercise of stock options	14,981	15,902
Excess tax benefits from stock-based compensation	10,825	8,002
Distribution of Aptevo	(45,000)	0
Contingent obligation payments	(1,226)	(5,427)
Net cash (used in) provided by financing activities	(20,420)	20,477
Effect of exchange rate changes on cash and cash equivalents	139	(16)
Net (decrease) increase in cash and cash equivalents	(13,863)	28,219
Cash and cash equivalents at beginning of period	312,795	280,499
Cash and cash equivalents at end of period	$ 298,932	$ 308,718